What are Analysts report about Texas Roadhouse, Inc.(NASDAQ:TXRH): Progenics Pharmaceuticals Inc.(NASDAQ:PGNX)

0
2

Texas Roadhouse, Inc. (TXRH) will report its next earnings on Feb 19 AMC. The company reported the earnings of $0.42/Share in the last quarter where the estimated EPS by analysts was $0.41/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 2.4%.

Many analysts are providing their Estimated Earnings analysis for Texas Roadhouse, Inc. and for the current quarter 19 analysts have projected that the stock could give an Average Earnings estimate of $0.82/share. These analysts have also projected a Low Estimate of $0.78/share and a High Estimate of $0.89/share.

In case of Revenue Estimates, 16 analysts have provided their consensus Average Revenue Estimates for Texas Roadhouse, Inc. as 693.94 Million. According to these analysts, the Low Revenue Estimate for Texas Roadhouse, Inc. is 687 Million and the High Revenue Estimate is 700.56 Million. The company had Year Ago Sales of 627.71 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for TXRH to be 7.9%. They are projecting Next Quarter growth of 11.29%. For the next 5 years, Texas Roadhouse, Inc. is expecting Growth of 9.75% per annum, whereas in the past 5 years the growth was 12.27% per annum.

Some buy side analysts are also providing their Analysis on Texas Roadhouse, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Texas Roadhouse, Inc. might touch $72 high while the Average Price Target and Low price Target is $63.75 and $53 respectively.

Texas Roadhouse, Inc. closed its last trading session at $59.75 with the loss of -0.03%. The Market Capitalization of the company stands at 4.33 Billion. The Company has 52-week high of $75.24 and 52-week low of $55.75. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -4.82% where SMA50 and SMA200 are -5.12% and -8.34% respectively. The Company Touched its 52-Week High on 09/07/18 and 52-Week Low on 03/23/18.

The Relative Volume of the company is 0.85 and Average Volume (3 months) is 803.02 million. The company’s P/E (price to earnings) ratio is 27.15 and Forward P/E ratio of 21.75.

The company shows its Return on Assets (ROA) value of 11.6%. The Return on Equity (ROE) value stands at 17.3%. While it’s Return on Investment (ROI) value is 17.3%.

While looking at the Stock’s Performance, Texas Roadhouse, Inc. currently shows a Weekly Performance of -1.92%, where Monthly Performance is -6.67%, Quarterly performance is -6.42%, 6 Months performance is -18.77% and yearly performance percentage is 1.17%. Year to Date performance value (YTD perf) value is 0.05%. The Stock currently has a Weekly Volatility of 1.45% and Monthly Volatility of 2.28%.

Progenics Pharmaceuticals Inc. (PGNX) will report its next earnings on Mar 14 BMO. The company reported the earnings of $-0.3/Share in the last quarter where the estimated EPS by analysts was $-0.18/share. The difference between the expected and actual EPS was $-0.12/share, which represents an Earnings surprise of -66.7%.

Many analysts are providing their Estimated Earnings analysis for Progenics Pharmaceuticals Inc. and for the current quarter 5 analysts have projected that the stock could give an Average Earnings estimate of $-0.11/share. These analysts have also projected a Low Estimate of $-0.18/share and a High Estimate of $-0.03/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Progenics Pharmaceuticals Inc. as 10.48 Million. According to these analysts, the Low Revenue Estimate for Progenics Pharmaceuticals Inc. is 4.1 Million and the High Revenue Estimate is 14.62 Million. The company had Year Ago Sales of 3.89 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for PGNX to be 85.7%. They are projecting Next Quarter growth of 31.58%. For the next 5 years, Progenics Pharmaceuticals Inc. is expecting Growth of 35.62% per annum, whereas in the past 5 years the growth was 18.89% per annum.

Some buy side analysts are also providing their Analysis on Progenics Pharmaceuticals Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Progenics Pharmaceuticals Inc. might touch $14 high while the Average Price Target and Low price Target is $10.92 and $6.5 respectively.

Progenics Pharmaceuticals Inc. closed its last trading session at $4.2 with the gain of 0.24%. The Market Capitalization of the company stands at 360.38 Million. The Company has 52-week high of $9.42 and 52-week low of $3.62. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -5.14% where SMA50 and SMA200 are -6.94% and -32.06% respectively. The Company Touched its 52-Week High on 08/06/18 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 1.06 and Average Volume (3 months) is 1.19 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -36.4%. The Return on Equity (ROE) value stands at -73.7%. While it’s Return on Investment (ROI) value is -44.6%.

While looking at the Stock’s Performance, Progenics Pharmaceuticals Inc. currently shows a Weekly Performance of 2.68%, where Monthly Performance is -8.48%, Quarterly performance is -3%, 6 Months performance is -43.18% and yearly performance percentage is -48.34%. Year to Date performance value (YTD perf) value is 0.24%. The Stock currently has a Weekly Volatility of 4.16% and Monthly Volatility of 4.66%.

SHARE